Emerging drugs for major depressive disorder

Expert Opinion on Emerging Drugs
Kevin Ryan Connolly, Michael E Thase

Abstract

Major depressive disorder (MDD) remains a major public health concern, and one that continues to suffer an incompletely-met need for effective and acceptable treatments. The development of antidepressants, to date, has focused primarily on increasing monoamine neurotransmission with increasing efficacy while minimizing adverse effects. Medications currently recommended as 'first-line' are far more tolerable than the older medications they replaced, but as many as 70% of patients continue to suffer significant depressive symptoms after treatment with one of these agents, and as many as 50% will discontinue a trial due to issues with acceptability. This review will summarize antidepressants that have recently entered the market as well as those still in development to help characterize the current state of antidepressant development. Currently available first-line antidepressants are reviewed with respect to efficacy and tolerability, and their weaknesses are discussed as targets for future development. The background, clinical trial data and potential significance of the three most recently introduced antidepressants (trazodone-ER, desvenlafaxine and vilazodone) and the most recently approved augmentation agents (aripiprazole an...Continue Reading

References

Aug 21, 1990·European Journal of Pharmacology·R Trullas, P Skolnick
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·N P NairC Pilapil
May 8, 1995·The Journal of Comparative Neurology·C RomanoJ W Olney
May 1, 1993·Brain Research. Molecular Brain Research·Y BesshoH Nawa
Mar 1, 1995·Behavior Genetics·N Breslau
Feb 25, 2000·Biological Psychiatry·R M BermanJ H Krystal
Jan 4, 2001·The American Journal of Psychiatry·R C SheltonH Y Meltzer
Jun 1, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·C A NaranjoU E Busto
Oct 25, 2002·Japanese Journal of Pharmacology·Daniel C BroomJames H Woods
Apr 23, 2003·Biological Psychiatry·Maurizio Fava
Jun 28, 2003·International Journal of Methods in Psychiatric Research·Philip S WangRonald C Kessler
Oct 25, 2003·Psychoneuroendocrinology·M CrassonJ J Legros
Nov 19, 2003·The European Journal of Neuroscience·Sara MorcuendeStephen P Hunt
Jan 28, 2004·Biological Psychiatry·S Neil VaishnaviMichael J Owens
Mar 31, 2004·Cellular and Molecular Neurobiology·Marcos Emílio dos Santos FrizzoDiogo Onofre Souza
Dec 16, 2005·The AAPS Journal·Lankupalle D Jayanthi, Sammanda Ramamoorthy
Feb 24, 2006·British Journal of Pharmacology·Shane A PerrineEllen M Unterwald
May 6, 2006·The Journal of Pharmacology and Experimental Therapeutics·Darlene C DeecherTerrance H Andree
Jul 1, 2006·Molecular Interventions·Emily M Jutkiewicz
Sep 2, 2006·The American Journal of Psychiatry·Ronald C KesslerPhilip S Wang
Oct 4, 2006·Archives of General Psychiatry·Maura L Furey, Wayne C Drevets
Mar 22, 2007·Expert Opinion on Therapeutic Targets·Andrew J Thompson, Sarah C R Lummis
Jul 4, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Vivien M HunotRachel C Churchill
Aug 11, 2007·International Clinical Psychopharmacology·Stuart A Montgomery, Siegfried Kasper
Oct 6, 2007·International Clinical Psychopharmacology·Stuart A MontgomeryMichael E Thase
Dec 7, 2007·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Tami BentonDwight L Evans

❮ Previous
Next ❯

Citations

Aug 15, 2013·Cell and Tissue Research·Vincenzo MicaleAlexandra Sulcova
Nov 21, 2013·CNS Spectrums·Meghan M Grady, Stephen M Stahl
Aug 8, 2013·Journal of Medicinal Chemistry·Jens-Uwe Peters
May 8, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elizabeth BrunnerMichael E Thase
Jan 9, 2014·Expert Opinion on Emerging Drugs·Paul A Keedwell, Allan H Young
Oct 23, 2012·The Urologic Clinics of North America·Michael W Rabow, Michael Xiang Lee
Aug 6, 2014·European Journal of Pharmacology·Olivia F O'LearyJohn F Cryan
Jun 10, 2015·Journal of Receptor and Signal Transduction Research·Colin G Rousseaux, Stephanie F Greene
Mar 25, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark J MillanSven Ove Ögren
Apr 4, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark J MillanSven Ove Ögren
May 28, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Francesc Artigas
Dec 25, 2012·Pharmacology & Therapeutics·Vincenzo MicaleFilippo Drago
May 28, 2013·Journal of Psychiatric Research·Adriana MedinaStanley J Watson
May 20, 2016·Current Psychiatry Reports·Faryal Mallick, Cheryl B McCullumsmith
Nov 1, 2016·Current Medical Research and Opinion·Michael ThaseElizabeth Pappadopulos
Nov 9, 2016·The Journal of Pharmacology and Experimental Therapeutics·Stephen FowlerNavita L Mallalieu
Aug 4, 2016·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Sidney H KennedyUNKNOWN CANMAT Depression Work Group
Jan 22, 2020·Psychiatric Services : a Journal of the American Psychiatric Association·Peter P ZandiJ Raymond DePaulo
Oct 2, 2019·Current Neuropharmacology·Kaipuzha Venu AthiraSumana Chakravarty
Apr 10, 2019·BMJ : British Medical Journal·Parashar RamanujHarold Alan Pincus
Mar 25, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Andrea Carlo RossettiRaffaella Molteni

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.